맞춤형 의료 시장 분석 및 예측(-2035년) : 유형별, 제품별, 서비스별, 기술별, 용도별, 최종 사용자별, 구성 요소별, 디바이스별, 프로세스별, 솔루션별

Personalized Medicine Market is anticipated to expand from $565.1 billion in 2024 to $1,127.4 billion by 2034, growing at a CAGR of approximately 8.4%. The Personalized Medicine Market encompasses healthcare solutions tailored to individual genetic profiles, lifestyle, and environment, enabling precise medical treatment. This market leverages genomics, diagnostics, and data analytics to optimize therapeutic outcomes. Rising demand for targeted therapies and advancements in biotechnology are propelling growth, fostering innovations in drug development, diagnostics, and patient care strategies.

The Personalized Medicine Market is experiencing robust growth, propelled by advancements in genomics and biotechnology. The therapeutics segment is the top performer, driven by targeted therapies and biologics, which offer tailored treatment options. Companion diagnostics follow closely, enabling precise patient stratification and monitoring. Within the therapeutics segment, oncology holds the leading position, benefiting from personalized cancer treatments that improve patient outcomes. Cardiovascular and neurology applications are also gaining momentum, reflecting an increasing focus on individualized care. The second highest performing segment is the personalized nutrition and wellness sector, which is expanding as consumers seek customized health solutions. Nutrigenomics and microbiome-based products are at the forefront, offering personalized dietary recommendations and supplements. Genetic testing services are also advancing, providing insights into individual health risks and predispositions. The integration of artificial intelligence and big data analytics is further enhancing the personalization of medical solutions, driving innovation and efficiency across the market.

Within the Personalized Medicine Market, innovative product launches and strategic pricing strategies are shaping market share dynamics. Companies are focusing on precision-based therapies, creating a competitive landscape driven by technological advancements. The market is witnessing a surge in demand for personalized treatment solutions, particularly in oncology and rare diseases. This trend is encouraging pharmaceutical companies to invest in research and development, fostering a culture of innovation. As a result, the market is experiencing a shift towards more targeted and effective treatment options, enhancing patient outcomes and driving industry growth. Competition benchmarking reveals that key players are intensifying efforts to differentiate through advanced genomics and bioinformatics. Regulatory influences, particularly in the U.S. and Europe, are pivotal in shaping market trajectories, with stringent guidelines ensuring safety and efficacy. The regulatory landscape is fostering innovation while maintaining high standards. Market analysis indicates a robust growth trajectory, driven by technological integration and strategic collaborations. The market is poised for expansion, with digital health technologies and personalized diagnostics offering lucrative opportunities. Challenges remain, including high costs and regulatory complexities, yet the potential for transformative healthcare solutions is immense.

Geographical Overview:

The personalized medicine market is witnessing robust growth across various regions, each presenting unique opportunities. North America leads the market, driven by advanced healthcare infrastructure and substantial investments in genomic research. The region's focus on precision medicine and patient-centric approaches enhances its market position. Europe follows closely, with strong government support and initiatives promoting personalized healthcare solutions. The region's emphasis on innovative healthcare practices fosters a conducive environment for market expansion. In the Asia Pacific, the market is expanding rapidly, propelled by rising healthcare expenditures and increasing awareness of personalized treatment options. Countries like China and India are emerging as key players, investing heavily in biotechnology and genomics. Latin America and the Middle East & Africa are also gaining traction. Brazil and the UAE are recognizing the potential of personalized medicine in improving healthcare outcomes, thus driving investments and fostering growth in these regions.

Global tariffs and geopolitical tensions are recalibrating the Personalized Medicine Market's dynamics, particularly in Japan, South Korea, China, and Taiwan. Japan and South Korea are fortifying their biopharmaceutical sectors, investing in local R&D to mitigate reliance on foreign imports. China is accelerating its indigenous biotech capabilities, driven by export restrictions and a desire for self-reliance. Taiwan, pivotal in precision medicine technologies, navigates geopolitical sensitivities while maintaining its innovation edge. The global market, buoyed by advancements in genomics and diagnostics, is robust, yet susceptible to supply chain disruptions and energy price volatility, exacerbated by Middle East conflicts. By 2035, the market's evolution will hinge on strategic regional collaborations and resilience against geopolitical and economic uncertainties.

Key Trends and Drivers:

The personalized medicine market is experiencing robust growth, propelled by advances in genomics and biotechnology. A significant trend is the integration of artificial intelligence and machine learning in drug development and diagnostics. These technologies enable the identification of biomarkers and the customization of treatment plans, enhancing patient outcomes. Another trend is the rising demand for targeted therapies, driven by the increasing prevalence of chronic diseases and the need for more effective treatments. Personalized medicine offers tailored approaches that improve efficacy and reduce adverse effects. Regulatory bodies are also playing a pivotal role by supporting precision medicine initiatives, which further accelerates market growth. Additionally, the expansion of direct-to-consumer genetic testing services is empowering individuals to make informed health decisions. This trend is complemented by the growing availability of companion diagnostics, which facilitate the selection of suitable therapies. The convergence of digital health technologies and personalized medicine is creating new opportunities for innovation and patient engagement, positioning the market for sustained expansion.

Research Scope:

• Estimates and forecasts the overall market size across type, application, and region.
• Provides detailed information and key takeaways on qualitative and quantitative trends, dynamics, business framework, competitive landscape, and company profiling.
• Identifies factors influencing market growth and challenges, opportunities, drivers, and restraints.
• Identifies factors that could limit company participation in international markets to help calibrate market share expectations and growth rates.
• Evaluates key development strategies like acquisitions, product launches, mergers, collaborations, business expansions, agreements, partnerships, and R&D activities.
• Analyzes smaller market segments strategically, focusing on their potential, growth patterns, and impact on the overall market.
• Outlines the competitive landscape, assessing business and corporate strategies to monitor and dissect competitive advancements.

Our research scope provides comprehensive market data, insights, and analysis across a variety of critical areas. We cover Local Market Analysis, assessing consumer demographics, purchasing behaviors, and market size within specific regions to identify growth opportunities. Our Local Competition Review offers a detailed evaluation of competitors, including their strengths, weaknesses, and market positioning. We also conduct Local Regulatory Reviews to ensure businesses comply with relevant laws and regulations. Industry Analysis provides an in-depth look at market dynamics, key players, and trends. Additionally, we offer Cross-Segmental Analysis to identify synergies between different market segments, as well as Production-Consumption and Demand-Supply Analysis to optimize supply chain efficiency. Our Import-Export Analysis helps businesses navigate global trade environments by evaluating trade flows and policies. These insights empower clients to make informed strategic decisions, mitigate risks, and capitalize on market opportunities.

TABLE OF CONTENTS

1 Executive Summary

• 1.1 Market Size and Forecast
• 1.2 Market Overview
• 1.3 Market Snapshot
• 1.4 Regional Snapshot
• 1.5 Strategic Recommendations
• 1.6 Analyst Notes

2 Market Highlights

• 2.1 Key Market Highlights by Type
• 2.2 Key Market Highlights by Product
• 2.3 Key Market Highlights by Services
• 2.4 Key Market Highlights by Technology
• 2.5 Key Market Highlights by Application
• 2.6 Key Market Highlights by End User
• 2.7 Key Market Highlights by Component
• 2.8 Key Market Highlights by Device
• 2.9 Key Market Highlights by Process
• 2.10 Key Market Highlights by Solutions

3 Market Dynamics

• 3.1 Macroeconomic Analysis
• 3.2 Market Trends
• 3.3 Market Drivers
• 3.4 Market Opportunities
• 3.5 Market Restraints
• 3.6 CAGR Growth Analysis
• 3.7 Impact Analysis
• 3.8 Emerging Markets
• 3.9 Technology Roadmap
• 3.10 Strategic Frameworks
  • 3.10.1 PORTER's 5 Forces Model
  • 3.10.2 ANSOFF Matrix
  • 3.10.3 4P's Model
  • 3.10.4 PESTEL Analysis

4 Segment Analysis

• 4.1 Market Size & Forecast by Type (2020-2035)
  • 4.1.1 Therapeutics
  • 4.1.2 Diagnostics
• 4.2 Market Size & Forecast by Product (2020-2035)
  • 4.2.1 Pharmacogenomics
  • 4.2.2 Companion Diagnostics
  • 4.2.3 Targeted Therapeutics
  • 4.2.4 Genetic Testing Kits
• 4.3 Market Size & Forecast by Services (2020-2035)
  • 4.3.1 Genomic Sequencing
  • 4.3.2 Molecular Diagnostics Services
  • 4.3.3 Personalized Medicine Consultations
• 4.4 Market Size & Forecast by Technology (2020-2035)
  • 4.4.1 Next-Generation Sequencing
  • 4.4.2 Polymerase Chain Reaction
  • 4.4.3 Bioinformatics
  • 4.4.4 Gene Editing
• 4.5 Market Size & Forecast by Application (2020-2035)
  • 4.5.1 Oncology
  • 4.5.2 Cardiology
  • 4.5.3 Neurology
  • 4.5.4 Infectious Diseases
  • 4.5.5 Respiratory Diseases
• 4.6 Market Size & Forecast by End User (2020-2035)
  • 4.6.1 Hospitals
  • 4.6.2 Clinics
  • 4.6.3 Academic Research Institutions
  • 4.6.4 Pharmaceutical Companies
• 4.7 Market Size & Forecast by Component (2020-2035)
  • 4.7.1 Software
  • 4.7.2 Hardware
  • 4.7.3 Services
• 4.8 Market Size & Forecast by Device (2020-2035)
  • 4.8.1 Wearable Devices
  • 4.8.2 Point-of-Care Devices
  • 4.8.3 Laboratory Instruments
• 4.9 Market Size & Forecast by Process (2020-2035)
  • 4.9.1 Biomarker Discovery
  • 4.9.2 Drug Development
  • 4.9.3 Clinical Trials
• 4.10 Market Size & Forecast by Solutions (2020-2035)
  • 4.10.1 Integrated Platforms
  • 4.10.2 Standalone Solutions
  • 4.10.3 Customized Solutions

5 Regional Analysis

• 5.1 Global Market Overview
• 5.2 North America Market Size (2020-2035)
  • 5.2.1 United States
    • 5.2.1.1 Type
    • 5.2.1.2 Product
    • 5.2.1.3 Services
    • 5.2.1.4 Technology
    • 5.2.1.5 Application
    • 5.2.1.6 End User
    • 5.2.1.7 Component
    • 5.2.1.8 Device
    • 5.2.1.9 Process
    • 5.2.1.10 Solutions
  • 5.2.2 Canada
    • 5.2.2.1 Type
    • 5.2.2.2 Product
    • 5.2.2.3 Services
    • 5.2.2.4 Technology
    • 5.2.2.5 Application
    • 5.2.2.6 End User
    • 5.2.2.7 Component
    • 5.2.2.8 Device
    • 5.2.2.9 Process
    • 5.2.2.10 Solutions
  • 5.2.3 Mexico
    • 5.2.3.1 Type
    • 5.2.3.2 Product
    • 5.2.3.3 Services
    • 5.2.3.4 Technology
    • 5.2.3.5 Application
    • 5.2.3.6 End User
    • 5.2.3.7 Component
    • 5.2.3.8 Device
    • 5.2.3.9 Process
    • 5.2.3.10 Solutions
• 5.3 Latin America Market Size (2020-2035)
  • 5.3.1 Brazil
    • 5.3.1.1 Type
    • 5.3.1.2 Product
    • 5.3.1.3 Services
    • 5.3.1.4 Technology
    • 5.3.1.5 Application
    • 5.3.1.6 End User
    • 5.3.1.7 Component
    • 5.3.1.8 Device
    • 5.3.1.9 Process
    • 5.3.1.10 Solutions
  • 5.3.2 Argentina
    • 5.3.2.1 Type
    • 5.3.2.2 Product
    • 5.3.2.3 Services
    • 5.3.2.4 Technology
    • 5.3.2.5 Application
    • 5.3.2.6 End User
    • 5.3.2.7 Component
    • 5.3.2.8 Device
    • 5.3.2.9 Process
    • 5.3.2.10 Solutions
  • 5.3.3 Rest of Latin America
    • 5.3.3.1 Type
    • 5.3.3.2 Product
    • 5.3.3.3 Services
    • 5.3.3.4 Technology
    • 5.3.3.5 Application
    • 5.3.3.6 End User
    • 5.3.3.7 Component
    • 5.3.3.8 Device
    • 5.3.3.9 Process
    • 5.3.3.10 Solutions
• 5.4 Asia-Pacific Market Size (2020-2035)
  • 5.4.1 China
    • 5.4.1.1 Type
    • 5.4.1.2 Product
    • 5.4.1.3 Services
    • 5.4.1.4 Technology
    • 5.4.1.5 Application
    • 5.4.1.6 End User
    • 5.4.1.7 Component
    • 5.4.1.8 Device
    • 5.4.1.9 Process
    • 5.4.1.10 Solutions
  • 5.4.2 India
    • 5.4.2.1 Type
    • 5.4.2.2 Product
    • 5.4.2.3 Services
    • 5.4.2.4 Technology
    • 5.4.2.5 Application
    • 5.4.2.6 End User
    • 5.4.2.7 Component
    • 5.4.2.8 Device
    • 5.4.2.9 Process
    • 5.4.2.10 Solutions
  • 5.4.3 South Korea
    • 5.4.3.1 Type
    • 5.4.3.2 Product
    • 5.4.3.3 Services
    • 5.4.3.4 Technology
    • 5.4.3.5 Application
    • 5.4.3.6 End User
    • 5.4.3.7 Component
    • 5.4.3.8 Device
    • 5.4.3.9 Process
    • 5.4.3.10 Solutions
  • 5.4.4 Japan
    • 5.4.4.1 Type
    • 5.4.4.2 Product
    • 5.4.4.3 Services
    • 5.4.4.4 Technology
    • 5.4.4.5 Application
    • 5.4.4.6 End User
    • 5.4.4.7 Component
    • 5.4.4.8 Device
    • 5.4.4.9 Process
    • 5.4.4.10 Solutions
  • 5.4.5 Australia
    • 5.4.5.1 Type
    • 5.4.5.2 Product
    • 5.4.5.3 Services
    • 5.4.5.4 Technology
    • 5.4.5.5 Application
    • 5.4.5.6 End User
    • 5.4.5.7 Component
    • 5.4.5.8 Device
    • 5.4.5.9 Process
    • 5.4.5.10 Solutions
  • 5.4.6 Taiwan
    • 5.4.6.1 Type
    • 5.4.6.2 Product
    • 5.4.6.3 Services
    • 5.4.6.4 Technology
    • 5.4.6.5 Application
    • 5.4.6.6 End User
    • 5.4.6.7 Component
    • 5.4.6.8 Device
    • 5.4.6.9 Process
    • 5.4.6.10 Solutions
  • 5.4.7 Rest of APAC
    • 5.4.7.1 Type
    • 5.4.7.2 Product
    • 5.4.7.3 Services
    • 5.4.7.4 Technology
    • 5.4.7.5 Application
    • 5.4.7.6 End User
    • 5.4.7.7 Component
    • 5.4.7.8 Device
    • 5.4.7.9 Process
    • 5.4.7.10 Solutions
• 5.5 Europe Market Size (2020-2035)
  • 5.5.1 Germany
    • 5.5.1.1 Type
    • 5.5.1.2 Product
    • 5.5.1.3 Services
    • 5.5.1.4 Technology
    • 5.5.1.5 Application
    • 5.5.1.6 End User
    • 5.5.1.7 Component
    • 5.5.1.8 Device
    • 5.5.1.9 Process
    • 5.5.1.10 Solutions
  • 5.5.2 France
    • 5.5.2.1 Type
    • 5.5.2.2 Product
    • 5.5.2.3 Services
    • 5.5.2.4 Technology
    • 5.5.2.5 Application
    • 5.5.2.6 End User
    • 5.5.2.7 Component
    • 5.5.2.8 Device
    • 5.5.2.9 Process
    • 5.5.2.10 Solutions
  • 5.5.3 United Kingdom
    • 5.5.3.1 Type
    • 5.5.3.2 Product
    • 5.5.3.3 Services
    • 5.5.3.4 Technology
    • 5.5.3.5 Application
    • 5.5.3.6 End User
    • 5.5.3.7 Component
    • 5.5.3.8 Device
    • 5.5.3.9 Process
    • 5.5.3.10 Solutions
  • 5.5.4 Spain
    • 5.5.4.1 Type
    • 5.5.4.2 Product
    • 5.5.4.3 Services
    • 5.5.4.4 Technology
    • 5.5.4.5 Application
    • 5.5.4.6 End User
    • 5.5.4.7 Component
    • 5.5.4.8 Device
    • 5.5.4.9 Process
    • 5.5.4.10 Solutions
  • 5.5.5 Italy
    • 5.5.5.1 Type
    • 5.5.5.2 Product
    • 5.5.5.3 Services
    • 5.5.5.4 Technology
    • 5.5.5.5 Application
    • 5.5.5.6 End User
    • 5.5.5.7 Component
    • 5.5.5.8 Device
    • 5.5.5.9 Process
    • 5.5.5.10 Solutions
  • 5.5.6 Rest of Europe
    • 5.5.6.1 Type
    • 5.5.6.2 Product
    • 5.5.6.3 Services
    • 5.5.6.4 Technology
    • 5.5.6.5 Application
    • 5.5.6.6 End User
    • 5.5.6.7 Component
    • 5.5.6.8 Device
    • 5.5.6.9 Process
    • 5.5.6.10 Solutions
• 5.6 Middle East & Africa Market Size (2020-2035)
  • 5.6.1 Saudi Arabia
    • 5.6.1.1 Type
    • 5.6.1.2 Product
    • 5.6.1.3 Services
    • 5.6.1.4 Technology
    • 5.6.1.5 Application
    • 5.6.1.6 End User
    • 5.6.1.7 Component
    • 5.6.1.8 Device
    • 5.6.1.9 Process
    • 5.6.1.10 Solutions
  • 5.6.2 United Arab Emirates
    • 5.6.2.1 Type
    • 5.6.2.2 Product
    • 5.6.2.3 Services
    • 5.6.2.4 Technology
    • 5.6.2.5 Application
    • 5.6.2.6 End User
    • 5.6.2.7 Component
    • 5.6.2.8 Device
    • 5.6.2.9 Process
    • 5.6.2.10 Solutions
  • 5.6.3 South Africa
    • 5.6.3.1 Type
    • 5.6.3.2 Product
    • 5.6.3.3 Services
    • 5.6.3.4 Technology
    • 5.6.3.5 Application
    • 5.6.3.6 End User
    • 5.6.3.7 Component
    • 5.6.3.8 Device
    • 5.6.3.9 Process
    • 5.6.3.10 Solutions
  • 5.6.4 Sub-Saharan Africa
    • 5.6.4.1 Type
    • 5.6.4.2 Product
    • 5.6.4.3 Services
    • 5.6.4.4 Technology
    • 5.6.4.5 Application
    • 5.6.4.6 End User
    • 5.6.4.7 Component
    • 5.6.4.8 Device
    • 5.6.4.9 Process
    • 5.6.4.10 Solutions
  • 5.6.5 Rest of MEA
    • 5.6.5.1 Type
    • 5.6.5.2 Product
    • 5.6.5.3 Services
    • 5.6.5.4 Technology
    • 5.6.5.5 Application
    • 5.6.5.6 End User
    • 5.6.5.7 Component
    • 5.6.5.8 Device
    • 5.6.5.9 Process
    • 5.6.5.10 Solutions

6 Market Strategy

• 6.1 Demand-Supply Gap Analysis
• 6.2 Trade & Logistics Constraints
• 6.3 Price-Cost-Margin Trends
• 6.4 Market Penetration
• 6.5 Consumer Analysis
• 6.6 Regulatory Snapshot

7 Competitive Intelligence

• 7.1 Market Positioning
• 7.2 Market Share
• 7.3 Competition Benchmarking
• 7.4 Top Company Strategies

8 Company Profiles

• 8.1 Illumina
  • 8.1.1 Overview
  • 8.1.2 Product Summary
  • 8.1.3 Financial Performance
  • 8.1.4 SWOT Analysis
• 8.2 Qiagen
  • 8.2.1 Overview
  • 8.2.2 Product Summary
  • 8.2.3 Financial Performance
  • 8.2.4 SWOT Analysis
• 8.3 Myriad Genetics
  • 8.3.1 Overview
  • 8.3.2 Product Summary
  • 8.3.3 Financial Performance
  • 8.3.4 SWOT Analysis
• 8.4 Genomic Health
  • 8.4.1 Overview
  • 8.4.2 Product Summary
  • 8.4.3 Financial Performance
  • 8.4.4 SWOT Analysis
• 8.5 Natera
  • 8.5.1 Overview
  • 8.5.2 Product Summary
  • 8.5.3 Financial Performance
  • 8.5.4 SWOT Analysis
• 8.6 Foundation Medicine
  • 8.6.1 Overview
  • 8.6.2 Product Summary
  • 8.6.3 Financial Performance
  • 8.6.4 SWOT Analysis
• 8.7 Adaptive Biotechnologies
  • 8.7.1 Overview
  • 8.7.2 Product Summary
  • 8.7.3 Financial Performance
  • 8.7.4 SWOT Analysis
• 8.8 Guardant Health
  • 8.8.1 Overview
  • 8.8.2 Product Summary
  • 8.8.3 Financial Performance
  • 8.8.4 SWOT Analysis
• 8.9 Invitae
  • 8.9.1 Overview
  • 8.9.2 Product Summary
  • 8.9.3 Financial Performance
  • 8.9.4 SWOT Analysis
• 8.10 Personalis
  • 8.10.1 Overview
  • 8.10.2 Product Summary
  • 8.10.3 Financial Performance
  • 8.10.4 SWOT Analysis
• 8.11 Care Dx
  • 8.11.1 Overview
  • 8.11.2 Product Summary
  • 8.11.3 Financial Performance
  • 8.11.4 SWOT Analysis
• 8.12 Blueprint Medicines
  • 8.12.1 Overview
  • 8.12.2 Product Summary
  • 8.12.3 Financial Performance
  • 8.12.4 SWOT Analysis
• 8.13 Blueprint Genetics
  • 8.13.1 Overview
  • 8.13.2 Product Summary
  • 8.13.3 Financial Performance
  • 8.13.4 SWOT Analysis
• 8.14 Grail
  • 8.14.1 Overview
  • 8.14.2 Product Summary
  • 8.14.3 Financial Performance
  • 8.14.4 SWOT Analysis
• 8.15 Freenome
  • 8.15.1 Overview
  • 8.15.2 Product Summary
  • 8.15.3 Financial Performance
  • 8.15.4 SWOT Analysis
• 8.16 Sema4
  • 8.16.1 Overview
  • 8.16.2 Product Summary
  • 8.16.3 Financial Performance
  • 8.16.4 SWOT Analysis
• 8.17 Tempus
  • 8.17.1 Overview
  • 8.17.2 Product Summary
  • 8.17.3 Financial Performance
  • 8.17.4 SWOT Analysis
• 8.18 Caris Life Sciences
  • 8.18.1 Overview
  • 8.18.2 Product Summary
  • 8.18.3 Financial Performance
  • 8.18.4 SWOT Analysis
• 8.19 Neo Genomics
  • 8.19.1 Overview
  • 8.19.2 Product Summary
  • 8.19.3 Financial Performance
  • 8.19.4 SWOT Analysis
• 8.20 Syapse
  • 8.20.1 Overview
  • 8.20.2 Product Summary
  • 8.20.3 Financial Performance
  • 8.20.4 SWOT Analysis

9 About Us

• 9.1 About Us
• 9.2 Research Methodology
• 9.3 Research Workflow
• 9.4 Consulting Services
• 9.5 Our Clients
• 9.6 Client Testimonials
• 9.7 Contact Us